As CD147 had elevated expression levels in tumor T cells from patients with ALL T-cell and T-cell lymphoma, it was considered a potential antigenic target of T-CAR cell therapy for T-ALL. This evidence concerns the gene BSG and T-cell non-Hodgkin lymphoma.